For Viracidal Ointment To Prevent And Treat Herpes
BOYNTON BEACH, Fla., Nov. 19 /PRNewswire/ -- Pure H20 Bio-Technologies
Inc. (OTC Bulletin Board: PHBT) announced today it has signed a Letter of
Intent to enter into an exclusive patent license agreement for a technology to
prevent and treat genital and oral herpes. The agreement with inventors, Mr.
Richard D. Polley and Mr. Paul Posten, is for worldwide distribution rights.
The treatment is applied through a viracidal ointment or cream which is
topically applied and kills 100% of both Herpes Complex viruses. This
technology has the potential to also prevent, treat and cure Herpes Zoster
cases, "shingles," and other skin viruses including STDs (Sexually Transmitted
Disease) and warts.
Mr. Joseph P. Doxey, president of Pure H20, said, "the market for this
breakthrough technology and its applications easily exceeds one billion
dollars in the U.S. alone."
This will be the fifth patent license agreement the company is involved
with for their breakthrough technologies. They currently own one patent for
the method to dispense iodine for potable water and have contracted for an
additional four patent license agreements. Three licenses are for the U.S.
and Canada; (i) the "Invisible Glove," a protective waterproof skin coating,
(ii) an agricultural application of their technology and (iii) a special
coating for plastics and metals. The fourth license for an aerosolized
foaming multipurpose soap is licensed worldwide.
Pure H20 Bio-Technologies, Inc. is a biotechnology company with a patented
proprietary water iodination process which effectively "kills" waterborne
viruses, bacteria and other microbial pathogens. They are engaged in the
development and marketing of products and systems which utilize this
technology to protect individuals against microbiological contamination and
disease.
This material was prepared by The Hawke Group, Inc. ("Hawke") for the
Company discussed herein, based upon Company supplied information or other
sources believed to be reliable. The information is not guaranteed by Hawke
for accuracy or to be all inclusive. The foregoing discussion contains
forward-looking statements that involve risks and uncertainties. Actual
results could differ from those discussed in this release. This material is
information only and is not an offer or solicitation to buy or sell the
securities. Hawke, its affiliates, and/or its officers, directors and
employees may from time to time have a position in these securities.
SOURCE Pure H2O Bio-Technologies, Inc.
-0- 11/19/97
/CONTACT: The Hawke Group, 954-564-7114/
/Web site: hawkegroup.com
(PHBT)
CO: Pure H2O Bio-Technologies, Inc.
ST: Florida
IN: MTC
SU: |
